NS Pharma Announces FDA Clearance to Initiate Phase II Study for NS-089/NCNP-02, an Exon 44 Skipping Candidate for the Treatment of Duchenne

April 18, 2023

On Friday, April 14, 2023, NS Pharma announced that the U.S. Food & Drug Administration (FDA) has agreed to the planned Phase II study of NS-089/NCNP02 for Duchenne muscular dystrophy.

Please read the full update on their shared press release.

Experience the magic this summer!

How is the rare disease community accomplishing goals?

Tune in on February 29 to hear from our panel and moderators on how they are accomplishing goals and living life to the fullest!

Your gift helps Jett Foundation provide programming and opportunities, such as Camp Promise, to many families impacted by Duchenne muscular dystrophy each year.

Accessible Vehicle Fund Applications Open